Determination of the maximum steady state of lactate (MLSS) in saliva: An alternative to blood lactate determination

Based on previous research which shows parallelism between the saliva and blood lactate response during incremental exercise, we hypothesized that a "maximum salivary lactate steady state" (saliva-MLSS) might exist. Thus, the aim of the present investigation was to establish 1) which lower limit for the increase in salivary lactate concentration during a constant workload (i.e., from the 10th to the 20th min) test could be used to determine the saliva-MLSS and 2) if the exercise intensity corresponding to the saliva-MLSS is identical to that evoking the (blood) MLSS. Twelve male amateur athletes of mean (+/-SD) age 24+/-5 year were selected for the study. Based on the results of a previous maximal cycle ergometer test for lactate threshold (LT) determination, each subject performed consecutive constant workload tests of 20-min duration on separate days for MLSS determination, Blood and saliva (25 mu l) samples were collected at 0, 10, and 20 min during the tests for lactate determination. A Student's t-test for paired data demonstrated that a salivary lactate increase of 0.8 mM corresponded to the saliva-MLSS. At this value, indeed, no significant differences were observed between the mean (V) over dot O-2, and W values corresponding to the MLSS and the saliva-MLSS. In conclusion, the present findings indicate that 0.8 mM is the lower limit for the increase in saliva lactate concentration during a constant load test and thus is that which might be used as a reference to determine saliva-MLSS. Furthermore, saliva-MLSS might be used as an alternative to MLSS determination in blood samples.

Characteristics of microRNAs and their potential relevance for the diagnosis and therapy of the acute respiratory distress syndrome: from bench to bedside

Acute respiratory distress syndrome (ARDS) is a complex disease associated with high morbidity and mortality. Biomarkers and specific pharmacologic treatment of the syndrome are lacking. MicroRNAs (miRNAs) are small (∼19–22 nucleotides) noncoding RNA molecules whose function is the regulation of gene expression. Their uncommon biochemical characteristics (eg, their resistance to degradation because of extreme temperature and pH fluctuations, freeze-thaw cycles, long storage times in frozen conditions, and RNAse digestion) and their presence in a wide range of different biological fluids and the relatively low number of individual miRNAs make these molecules good biomarkers in different clinical conditions. In addition, miRNAs are suitable therapeutic targets as their expression can be modulated by different available strategies. The aim of the present review is to offer clinicians a global perspective of miRNA, covering their structure and nomenclature, biogenesis, effects on gene expression, regulation of expression, and features as disease biomarkers and therapeutic targets, with special attention to ARDS. Because of the early stage of research on miRNAs applied to ARDS, attention has been focused on how knowledge sourced from basic and translational research could inspire future clinical studies.